Clinical trials: Heme Malignancy

Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

• Active, not recruiting
• Age: All ages
• Phase 2
• Results posted

This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis.

Trial name

NCT03642626

Testing

KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses

Where

United States

Volunteers

150 people

Sponsor

Masonic Cancer Center, University of Minnesota